Is PT-141 (Bremelanotide) Legal in Ohio?

What Exactly Is PT-141 (Bremelanotide)?

PT-141 is the research and clinical-development name for bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. It binds primarily to MC3R and MC4R receptors in the central nervous system to modulate sexual desire. The FDA approved it in June 2019 under the brand name Vyleesi (manufactured by AMAG Pharmaceuticals, later acquired by Palatin Technologies' licensee) for treating acquired, generalized hypoactive sexual desire disorder in premenopausal women.

Mechanism of Action

Unlike phosphodiesterase-5 inhibitors such as sildenafil, bremelanotide does not act on the vasculature directly. It targets hypothalamic pathways that regulate sexual motivation. The Phase 3 RECONNECT trials (two replicate studies, combined N = 1,247) showed statistically significant improvements in desire and reductions in distress versus placebo after at-home dosing (P<0.001 for both co-primary endpoints) (1).

How It Differs from Other Sexual-Function Drugs

Bremelanotide is dosed on-demand, approximately 45 minutes before anticipated sexual activity. The approved dose is 1.75 mg subcutaneous. It is not taken daily. That on-demand profile separates it from flibanserin (Addyi), the once-daily oral HSDD drug, and from testosterone-based therapies that require chronic administration.

Federal Legal Framework: FDA Approval and Scheduling Status

Understanding PT-141's federal status is the first step before examining Ohio-specific rules. Federal law governs drug approval, scheduling, and compounding standards that every state, including Ohio, must follow.

FDA Approval Status

Bremelanotide holds NDA 210557 (Vyleesi, 1.75 mg/0.3 mL solution for subcutaneous injection). The FDA approved this indication: "treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance" (2).

Because bremelanotide has an FDA-approved finished-drug product, its legal standing is meaningfully different from unapproved peptides such as BPC-157 or TB-500. Prescribers can write for the approved Vyleesi product through any licensed Ohio pharmacy.

DEA Scheduling

As of January 2025, bremelanotide is not listed in DEA Schedules I through V under the Controlled Substances Act (3). This means a DEA registration is not required for a physician to prescribe it, and patients do not face felony-level possession exposure the way they would with a Schedule I substance. Possessing any prescription drug without a valid prescription still violates federal and Ohio law.

Compounding Under 503A and 503B

This is where the legal picture becomes more complicated. The FDA Drug Supply Chain Security Act and Section 503A/503B of the Federal Food, Drug, and Cosmetic Act set rules for compounding pharmacies.

The FDA maintains a list of bulk drug substances that may be used in compounding. For 503B outsourcing facilities (which compound without patient-specific prescriptions for office use), bremelanotide appears on the FDA's Category 2 Bulks List. Category 2 means the substance is under consideration and may be used for compounding by 503B facilities while review is ongoing, but the FDA has raised questions about clinical need given the existence of an approved product (4).

For 503A pharmacies (traditional compounding pharmacies filling patient-specific prescriptions), federal policy is more restrictive. The FDA's general position is that 503A pharmacies should not compound a drug that is essentially a copy of a commercially available approved product unless there is a documented clinical difference, such as a patient-specific allergy to an excipient or a required alternative concentration. If a prescriber documents a valid reason, a licensed 503A pharmacy in Ohio may prepare compounded bremelanotide. Without that documentation, the pharmacy risks an FDA compliance action.

Ohio-Specific Legal Framework

Ohio does not have a state law that independently bans or restricts bremelanotide beyond what federal law requires. What governs PT-141 access in Ohio is a combination of the Ohio Medical Practice Act, the Ohio State Board of Pharmacy regulations, and federal compounding standards that Ohio pharmacies must follow.

Ohio State Board of Pharmacy Rules

The Ohio State Board of Pharmacy (OSBP) licenses and regulates all pharmacies operating in Ohio, including compounding pharmacies. Ohio Revised Code Chapter 4729 and the Ohio Administrative Code Chapter 4729 govern pharmacy practice. Ohio-licensed 503A compounding pharmacies must comply with USP Chapter 797 sterile compounding standards, because bremelanotide is a sterile injectable. The OSBP regularly inspects compounding pharmacies for compliance with these standards (5).

An Ohio pharmacy that compounds bremelanotide without a valid patient-specific prescription or without meeting the federal exemption criteria for 503B status would be operating outside both state and federal law.

Ohio Medical Practice Act and Prescribing Authority

Under Ohio Revised Code Section 4731, licensed physicians (MD/DO), advanced practice registered nurses (APRNs) with prescriptive authority, and physician assistants (PAs) with the appropriate collaborative agreement may prescribe bremelanotide. Off-label prescribing, including for male sexual dysfunction, is legally permissible under the Medical Practice Act, provided the prescriber documents clinical justification. Ohio does not restrict off-label prescribing of non-controlled substances by statute.

Telehealth Prescribing in Ohio

Ohio Senate Bill 129 (enacted 2021) and subsequent Ohio Administrative Code updates affirmed that telehealth prescribing is legal for non-controlled substances once a valid patient-provider relationship exists. A provider using audio-video telehealth can evaluate a patient, establish a diagnosis, and prescribe bremelanotide without an in-person visit, as long as the standard of care is met. This opens the door for Ohio patients in rural areas or those without local sexual-health specialists to access legitimate prescriptions (6).

How to Get PT-141 (Bremelanotide) Legally in Ohio

There are two legitimate access paths: the FDA-approved branded product, and compounded bremelanotide from a qualifying pharmacy.

Path 1: Vyleesi (Branded, FDA-Approved)

A prescriber with an Ohio license writes a prescription for Vyleesi 1.75 mg auto-injector. The patient fills it at any retail or mail-order pharmacy with the product in stock or available to order. Insurance coverage is limited. The manufacturer's patient assistance program has historically offered savings cards, but out-of-pocket costs can be significant.

Steps:

1. Schedule a visit with a gynecologist, urologist, sexual-health specialist, or telehealth provider licensed in Ohio.
2. Complete a validated desire-assessment tool (the Female Sexual Function Index or the Female Sexual Distress Scale-Revised are commonly used).
3. Rule out reversible causes of low libido: hormonal imbalance, medication side effects, relationship factors, psychiatric conditions.
4. Receive a written prescription for Vyleesi.
5. Fill at a licensed Ohio pharmacy or through a pharmacy benefit manager.

Path 2: Compounded Bremelanotide

Compounded bremelanotide (often dispensed as a multi-dose vial with a separate syringe) may be available at a lower cost. This path requires the prescribing provider to document a valid clinical reason for the compounded form rather than the approved product. Examples include a documented excipient allergy or a clinically indicated concentration not commercially available.

The compounding pharmacy must be licensed in Ohio (or licensed in its home state and registered to ship into Ohio) and must comply with USP 797 standards for sterile preparations. Patients should verify the pharmacy's NABP accreditation and ask the pharmacy directly whether their bremelanotide supply comes from an FDA-registered supplier.

What Is Not Legal

Purchasing PT-141 powder or pre-filled vials from overseas websites, unregulated domestic "research chemical" vendors, or any source not operating as a licensed pharmacy is not legal for human use in Ohio (or any U.S. State). Such products are not subject to quality controls. The FDA has issued warning letters to vendors selling peptides labeled "for research use only" when the products are clearly marketed for human self-administration (7).

Clinical Profile: Efficacy and Safety Data

Before seeking a prescription, patients and providers should review what the clinical evidence actually shows.

RECONNECT Phase 3 Trials

The two key RECONNECT trials enrolled a combined 1,247 premenopausal women with HSDD. Participants self-administered bremelanotide 1.75 mg subcutaneous approximately 45 minutes before anticipated activity for 24 weeks. The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Revised item 13 score. Both studies met their co-primary endpoints with statistically significant improvements versus placebo (P<0.001) (1).

Common Adverse Effects

The most frequent adverse effect is nausea, reported in approximately 40% of participants in the RECONNECT trials. Flushing occurred in about 20%, and headache in about 11%. Nausea was typically mild to moderate and lasted less than 12 hours. Taking a high-fat meal before dosing increased nausea risk; the prescribing information advises against this. Transient increases in blood pressure (mean 6 mmHg systolic, returning to baseline within 12 hours) were also observed. Bremelanotide is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension (2).

Off-Label Use in Men

No FDA-approved indication exists for bremelanotide in men. However, early clinical data from Palatin Technologies' Phase 2 trials in men with erectile dysfunction and animal studies suggest melanocortin receptor activity affects male sexual response. Off-label prescription in men is legal in Ohio under the state's broad prescriber discretion for non-controlled substances, but the evidence base is thinner than for the HSDD indication. Providers prescribing off-label should document the rationale, discuss the off-label nature with the patient, and obtain informed consent. The Endocrine Society's 2019 clinical practice guidelines for male hypogonadism do not address bremelanotide specifically, which reflects the limited data in this population (8).

Off-Label Use in Postmenopausal Women

The RECONNECT trials excluded postmenopausal women. Some providers use bremelanotide off-label in this population, but the data supporting this practice comes primarily from open-label and smaller studies. The Menopause Society (formerly NAMS) 2022 position statement on sexual function in menopause does not list bremelanotide as a recommended therapy for postmenopausal HSDD, citing the absence of trials in this group (9).

Comparing Legal Access Options in Ohio

| Access Route | Legal? | Prescription Needed? | Quality Assurance | |---|---|---|---| | Vyleesi (branded) from licensed Ohio pharmacy | Yes | Yes | FDA-approved manufacturing | | Compounded bremelanotide from licensed 503A pharmacy (with documented clinical reason) | Yes, with conditions | Yes | USP 797 compliance required | | Compounded bremelanotide from licensed 503B outsourcing facility | Yes, Category 2 conditions apply | Yes (for patient-specific use) | FDA-registered facility standards | | Overseas online vendors / "research chemical" sites | No | N/A | None | | Domestic unregulated vendors | No | N/A | None |

What Your Ohio Provider Should Document

A well-documented chart note protects both the patient and the prescriber. Ohio Medical Board guidance on prescribing standards expects records to include the clinical indication, any prior therapies tried, the patient's understanding of benefits and risks, and (for off-label use) the evidence basis for the prescription. For bremelanotide specifically, providers should document:

• A confirmed diagnosis of HSDD or the specific clinical rationale if prescribing off-label
• Validated screening scores (Female Sexual Function Index, Female Sexual Distress Scale-Revised, or comparable tool)
• Baseline blood pressure measurement, given the drug's transient pressor effect
• Exclusion of cardiovascular contraindications
• Counseling on nausea management (avoid high-fat meals, consider prophylactic ondansetron if nausea has been problematic)
• The reason for compounded form over Vyleesi, if applicable

The American Urological Association's 2021 guidelines on female sexual dysfunction do not yet include a specific bremelanotide recommendation section, but they affirm the importance of thorough evaluation before pharmacologic treatment (10).

Frequently Asked Questions